Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.71 |
| ▸ | HPGD | P15428 | 4/20 | 0.58 |
| ▸ | GRM5 | P41594 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 4/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3170903 | 0.83 | P2RX7 (0.57) | P2RX7HPGDGRM5NPC1RAB9A | |
| SCHEMBL534385 | 0.83 | P2RX7 (1.00) | P2RX7HPGDNPC1RAB9AKDM4E | |
| SCHEMBL363351 | 0.83 | NPC1 (0.60) | P2RX7HPGDGRM5NPC1RAB9A | |
| SCHEMBL28583422 | 0.82 | P2RX7 (0.97) | P2RX7HPGDNPC1RAB9AKDM4E | |
| SCHEMBL3172457 | 0.81 | TAS1R3 (0.59) | P2RX7HPGDNPC1RAB9AL3MBTL1 | |
| SCHEMBL695642 | 0.81 | P2RX7 (0.71) | P2RX7HPGDNPC1RAB9AL3MBTL1 | |
| SCHEMBL29615916 | 0.81 | P2RX7 (0.71) | P2RX7HPGDNPC1RAB9AL3MBTL1 | |
| SCHEMBL1741628 | 0.81 | P2RX7 (0.71) | P2RX7HPGDNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL30786170 | 0.81 | P2RX7 (0.54) | P2RX7HPGDGRM5NPC1RAB9A | |
| SCHEMBL23462320 | 0.77 | NPC1 (0.55) | P2RX7GRM5NPC1RAB9ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8138340-B2 | Bicyclononene derivatives | ACTELION PHARMACEUTICALS LTD. (CH) | 2012-03-20 | — | — | US | disclosed |
| EP-1786814-B1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2010-03-31 | — | — | EP | disclosed |
| US-20090306123-A1 | Bicyclononene derivaties | ACTELION PHARMACEUTICALS LTD. (CH) | 2009-12-10 | — | — | US | disclosed |
| EP-1786814-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2007-05-23 | — | — | EP | disclosed |
| WO-2006021402-A1 | BICYCLONONENE DERIVATIVES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD. (CH) | 2006-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306123-A1 | Bicyclononene derivaties | REN, ACE, CYP51A1 | P2RX7 1680/4885HPGD 176/4885GRM5 1670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.